A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
about
Neutral polymorphisms in putative housekeeping genes and tandem repeats unravels the population genetics and evolutionary history of Plasmodium vivax in IndiaTrafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalizationSelective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptorsPeptidomimetics as a new generation of antimicrobial agents: current progressCrystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptorThe anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptorTargeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogensInhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosisA binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNASuccessful identification of novel agents to control infectious diseases from screening mixture-based peptide combinatorial libraries in complex cell-based bioassays.Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands.HIV-1 envelope determinants for cell tropism and chemokine receptor use.The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus.Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.Identification of CXCR4 domains that support coreceptor and chemokine receptor functionsCXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.The role of chemokine receptors in HIV infection.Interference with the signaling capacity of CC chemokine receptor 5 can compromise its role as an HIV-1 entry coreceptor in primary T lymphocytes.Anti-HIV drug development through computational methods.Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Antigenically distinct conformations of CXCR4.Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.A whole genome association study of mother-to-child transmission of HIV in Malawi.Viral exploitation and subversion of the immune system through chemokine mimicry.Novel compounds in preclinical/early clinical development for the treatment of HIV infections.Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domainsChemokines and their receptors in infectious disease.Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effectsNew anti-HIV agents and targets.Coreceptor usage and biological phenotypes of HIV-1 isolates.
P2860
Q21562240-617FA72C-A872-4466-BB6D-5421230FD513Q22010658-483B8A87-0FCD-4A4D-8406-F5E067406035Q24673389-539697E5-2355-4A35-A873-981A8BF25900Q24682714-7149D7C5-EF12-4FA9-A0D2-26DADBF646CCQ27026959-895C61F7-EAA4-43C1-B144-AFD4D5532615Q27758437-D38AA80C-7F5B-4BEE-8668-C4C4B2480CD1Q28216327-9F30CF84-5A2B-49A2-88EA-4EAA0318DDBBQ28304369-9962E700-1F51-4ED9-AD91-411D2F3C0CC2Q28343496-71747525-7C9D-4E6D-A708-B31AB12D9C0EQ28343812-42AADCD7-1189-4021-8869-AB564C32EB31Q28344177-46BB23C1-E81D-4E80-9A85-DD24E96E4B2AQ28344310-D8B0ECF2-C751-4DD7-A416-0A4D0BF9AF96Q28345233-7299840F-F46D-4390-818C-8B814CCB63CFQ28478188-AAC73D05-1300-49BA-A64E-5C6D14892952Q30937880-4CBD259D-1B2A-4126-AB96-ED5B16F6CF84Q33541775-03468D59-2AE1-4F03-97CC-11390583B86BQ33637941-8D10F627-8946-4A46-8174-286410D8AC8EQ33637946-F4F3340F-42C2-4B4A-A569-6D26406B1546Q33637951-8D3B92E4-8792-490A-A2FE-475C15E6A9C0Q33639712-B4465B9E-939F-48F6-969C-4E638A2CB944Q33643223-60B371D9-0DFE-4860-A1CA-D8C8F0154B5AQ33677057-F9CCABE7-ED05-43B4-896B-E0B8EBBF48FBQ33711682-AD4DD86B-60B8-434A-AC72-54BA1863B50EQ33728885-30E53822-67EC-4B71-A892-39220C2CC3BCQ33803979-115EBEE5-2CD1-4A55-A1D8-D5E9D3BC5320Q33804495-4ED5EB32-B825-4225-8C9F-197BF0D09C21Q33818747-B49CEBF0-E35B-453B-99F4-933C8144505EQ33822395-5E6C355A-270B-4F87-A84B-7ED90E7F7BE2Q33845055-233EC717-2E1E-4404-A079-7236B5AFA376Q33858057-4A889DCC-A93C-480E-9B39-301BF70B5C40Q33865715-F71B52BE-0568-4E94-B582-9754D79B8D1CQ33933260-25E6EF7A-80AC-45FF-926B-AACD1299B2A3Q33966254-1165ADAB-5FE0-4492-898A-5268ECA63C88Q34045610-20976D45-C366-4EF0-B1F0-53A0D8BD4BE5Q34129756-B1BC640E-F697-4606-8ABB-25BA152EABBBQ34483653-6A69C118-E9C0-44C1-8F88-2975018ECA17Q34569177-601FF79F-37B9-41C9-A631-21891D3B557DQ34691351-C47600C1-6074-4152-B1F1-B5FDE32287A5Q34944447-3FFF83BA-14BF-4C63-A3CD-7C0355A49CFDQ34999203-43AE48E8-0E02-4642-B461-59AD7827A270
P2860
A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@ast
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@en
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@nl
type
label
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@ast
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@en
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@nl
prefLabel
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@ast
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@en
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@nl
P2093
P2860
P356
P1476
A small-molecule inhibitor dir ...... its use as an HIV-1 coreceptor
@en
P2093
B J Doranz
K Grovit-Ferbas
M P Sharron
W A O'Brien
P2860
P304
P356
10.1084/JEM.186.8.1395
P407
P577
1997-10-20T00:00:00Z